Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erdosteine + bepotastine besilate
- Development stage
- Unknown
- Lead developer
- Edmond Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erdosteine + bepotastine besilate is a combination therapy being developed by Daewoong Pharmaceutical Co. Ltd. for the treatment of respiratory and allergic conditions. Erdosteine is a mucolytic prodrug whose active metabolites contain free sulfhydryl groups that reduce the viscosity of bronchial secretions by breaking disulfide bonds in mucoproteins. It also exhibits antioxidant and anti-inflammatory activities. Bepotastine besilate is a second-generation, non-sedating antihistamine that acts as a selective antagonist at the histamine H1 receptor and also provides mast cell stabilization. This combination is intended to address the overlapping symptoms of chronic obstructive pulmonary disease (COPD) or bronchitis and allergic manifestations like allergic rhinitis or urticaria. A Phase 1 clinical trial has evaluated the pharmacokinetic interactions between these two agents.
- Brand names
- Talion
- Other names
- erdosteine + bepotastine besilate
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on erdosteine + bepotastine besilate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erdosteine + bepotastine besilate.